- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07816068
Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery
14 september 2026 uppdaterad av: Youn Joung Cho, MD, PhD, Seoul National University Hospital
Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery: A Randomized Controlled Trial
The purpose of this study is to compare remimazolam- and propofol-based anesthesia for their effects on postoperative cognitive dysfunction in patients undergoing aortic arch surgery.
These procedures involve a substantial risk of cerebral ischemia and reperfusion injury, which may contribute to postoperative cognitive decline.
Although experimental studies have suggested potential neuroprotective effects of remimazolam, clinical evidence in patients undergoing high-risk aortic arch surgery remains limited.
This prospective, randomized controlled trial will compare the incidence of postoperative cognitive dysfunction between patients receiving remimazolam- or propofol-based anesthesia.
In addition, changes in circulating neuroinflammatory and neuronal injury biomarkers will be evaluated to explore the potential mechanisms underlying any neuroprotective effect of remimazolam.
The findings may provide clinical evidence to guide anesthetic selection and improve neurological outcomes in patients undergoing aortic arch surgery.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
80
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Youn Joung Cho, M.D., Ph.D.
- Telefonnummer: 82-2-2072-2467
- E-post: mingming7@gmail.com
Studieorter
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
Kontakt:
- Youn Joung Cho, MD. PhD.
- Telefonnummer: 82-2-2072-3108
- E-post: mingming7@gmail.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Adults aged 19 years or older
- Patients scheduled to undergo total or partial aortic arch replacement for aortic arch disease, with planned circulatory arrest and/or selective cerebral perfusion as a cerebral protection strategy during surgery
Exclusion Criteria:
- Pre-existing cognitive impairment, defined as Mini-Mental State Examination (MMSE) score <24
- Acute cerebral hemorrhage or cerebral infarction within the previous 3 months
- History of hypersensitivity to remimazolam or other benzodiazepines
- History of alcohol or substance abuse
- Chronic use of opioids or benzodiazepines
- Severe hepatic impairment (Child-Pugh class C)
- Acute or chronic renal failure requiring dialysis Emergency surgery or acute aortic dissection
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Remimazolam group
Remimazolam Besylate (2mg/mL)
|
- Continuous drug: remimazolam diluted to 2 mg/mL in normal saline - Maintenance: 1-2 mg/kg/h (titrated to BIS 40-60, max 2 mg/kg/h)
|
|
Experimentell: Propofol group
Propofol (20mg/mL)
|
Continuous drug: propofol (undiluted, 20 mg/mL) - Administration: target-controlled infusion (TCI, Marsh model) - Maintenance: 1-1.5 μg/mL (titrated to BIS 40-60)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of postoperative cognitive decline
Tidsram: Preoperative baseline to postoperative day 7 or before hospital discharge
|
Postoperative cognitive function will be assessed using the Korean Mini-Mental State Examination (K-MMSE) and the Korean version of the Montreal Cognitive Assessment (MoCA-K).
Both assessments will be performed preoperatively and again on postoperative day 7 or before hospital discharge.
Postoperative cognitive dysfunction will be defined as a decrease of ≥2 points from the preoperative baseline score in either the K-MMSE or MoCA-K.
|
Preoperative baseline to postoperative day 7 or before hospital discharge
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in plasma IL-1β concentration
Tidsram: Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
|
Plasma interleukin-1 beta (IL-1β) concentration will be measured at preoperative baseline and 2-4 hours after completion of cardiopulmonary bypass.
The change from baseline will be compared between the remimazolam and propofol groups.
Plasma IL-1β concentration will be measured in pg/mL using the Meso Scale Discovery assay.
|
Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
|
|
Change in plasma TNF-α concentration
Tidsram: Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
|
Plasma tumor necrosis factor-alpha (TNF-α) concentration will be measured at preoperative baseline and 2-4 hours after completion of cardiopulmonary bypass.
The change from baseline will be compared between the remimazolam and propofol groups.
Plasma TNF-α concentration will be measured in pg/mL using the Meso Scale Discovery assay.
|
Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
|
|
Change in plasma IL-6 concentration
Tidsram: Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
Plasma interleukin-6 (IL-6) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass.
The change from baseline will be compared between the remimazolam and propofol groups.
Plasma IL-6 concentration will be measured in pg/mL using the Meso Scale Discovery assay.
|
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
|
Change in plasma IL-10 concentration
Tidsram: Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
Plasma interleukin-10 (IL-10) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass.
The change from baseline will be compared between the remimazolam and propofol groups.
Plasma IL-10 concentration will be measured in pg/mL using the Meso Scale Discovery assay.
|
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
|
Change in plasma HMGB1 concentration
Tidsram: Preoperative baseline through 24 hours after completion of cardiopulmonary bypass
|
Plasma high mobility group box 1 (HMGB1) concentration will be measured at preoperative baseline, 2-4 hours after completion of cardiopulmonary bypass, and 24 hours after completion of cardiopulmonary bypass.
Changes from baseline will be compared between the remimazolam and propofol groups.
Plasma HMGB1 concentration will be measured in pg/mL using the Multiplex bead assay.
|
Preoperative baseline through 24 hours after completion of cardiopulmonary bypass
|
|
Change in plasma GFAP concentration
Tidsram: Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
Plasma glial fibrillary acidic protein (GFAP) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass.
The change from baseline will be compared between the remimazolam and propofol groups.
GFAP will be analyzed using the Single Molecule Array (Simoa) assay.
|
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of postoperative delirium
Tidsram: Preoperative baseline to postoperative day 7 or before hospital discharge
|
Postoperative delirium will be assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
The incidence of postoperative delirium will be compared between the remimazolam and propofol groups.
|
Preoperative baseline to postoperative day 7 or before hospital discharge
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 oktober 2026
Primärt slutförande (Beräknad)
1 oktober 2027
Avslutad studie (Beräknad)
30 november 2027
Studieregistreringsdatum
Först inskickad
7 september 2026
Först inskickad som uppfyllde QC-kriterierna
7 september 2026
Första postat (Faktisk)
11 september 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 september 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 september 2026
Senast verifierad
1 september 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neurologiska manifestationer
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Mentala störningar
- Postoperativa komplikationer
- Patologiska processer
- Förvirring
- Neurobehavioral manifestationer
- Neurokognitiva störningar
- Aorta sjukdomar
- Aneurysm
- Delirium
- Aortaaneurysm
- Aortaaneurysm, thorax
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Emergence Delirium
- Aneurysm, aortabåge
- Organiska kemikalier
- Kolväten
- Kolväten, cykliska
- Kolväten, aromatisk
- Fenoler
- Bensiverivat
- Propofol
Andra studie-ID-nummer
- Arch_RMZ vs PPF
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .